A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

Clinical trial NCT00811733 · COMPLETED

Trial details

NCT number: NCT00811733
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Waldenstrom Macroglobulinaemia

Start date: 2009-03-01
Primary completion: 2011-06-01
Enrollment: 37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.